Benitec Biopharma Inc.

NASDAQ:BNTC

Biotechnology

Healthcare
$8.27 +3.05%

+$0.36 today

Market cap
$288.53M
Beta
0.28
P/E (TTM)
-12.3
EPS (TTM)
-$0.99
52W Low $9.85High $16.76

Volume 0.13M

Average 0.11M

BNTC Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Benitec Biopharma Inc.NASDAQ: BNTC

Accounts Receivables · Q3 FY2026 · quarter ended Mar 2026

Accounts receivables turns negative

Q3 FY2026 accounts receivables was -$122.05K, compared with $0 a year earlier. Trailing-twelve-month accounts receivables was $8.07K. Over 3 fiscal years it compounded at +481.9% a year.

Context

  • Accounts receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near -$122.05K or moves back toward the trailing-twelve-month quarterly average of $2.02K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$122.05K-199.2% QoQ
Last fiscal yearJun 2025
$197K+211.9% YoY
LTMMar 2026
$8.07K-96.4% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+211.9%——
3-year CAGR+481.9%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
197K USD
Year-over-year change
+211.9%
4-year CAGR
+62.9%

Accounts Receivables vs competitors

How BNTC compares with its peers on the latest reported figures

  • BNTC's LTM Mar 2026 accounts receivables of $8.07K is the 6th largest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of -96.4% is the 5th highest of 6, against a peer median of +96.6%.
  • Over three fiscal years its annual growth of +481.9% compares with a peer median of -68.7%.
BNTC Competitors Peer median
Accounts Receivables for BNTC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AUTLAutolus Therapeutics plcLTM Mar 2026$13.46M -6.1%—14.5%
XOMAXOMA Royalty Corp.LTM Mar 2026$1.6M +128.9%—4.4%
QSIQuantum-Si incorporatedLTM Mar 2026$683K +174.7%—36.9%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$586K +96.6%—4.0%
PRTCPureTech Health plcFY2025$236.55K -137.6%-68.7%5.1%
BNTCBenitec Biopharma Inc.LTM Mar 2026$8.07K -96.4%+481.9%—
SLDBSolid Biosciences Inc.LTM Mar 2026$0 ———
NGNENeurogene Inc.LTM Mar 2026$0 ———
OCGNOcugen, Inc.LTM Mar 2026$0 ——0.0%
GALTGalectin Therapeutics Inc.LTM Mar 2026$0 ———
Peer median (excluding BNTC) $0+96.6%-68.7%4.8%

Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Net Income(13.88M)(18.21M)(19.56M)(21.75M)(37.92M)
Depreciation & Amortization424K392K381K343K396K
Deferred Income Tax00(714K)00
Stock-Based Compensation634K870K452K830K17.43M
Change in Working Capital8K1.04M714K1.17M(2.73M)
Accounts Receivables28K1K(50K)(176K)197K
Inventory(83K)(1.09M)(1.31M)00
Accounts Payables55K1.09M1.36M0(2.38M)
Other Working Capital8K1.04M714K1.35M(548K)
Other Non-Cash Items(16K)10K717K1K(764K)
Operating Cash Flow(12.83M)(15.9M)(18.01M)(19.4M)(23.59M)
Capital Expenditures(221K)(13K)(1K)(179K)(18K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(221K)(13K)(1K)(179K)(18K)
Debt Repayment00000
Common Stock Issued25.75M017.88M70.88M70.49M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(3.23M)0(1.87M)(2.85M)0
Financing Cash Flow22.52M016.02M68.03M70.49M
Effect of Forex Changes499K204K412K(8K)49K
Net Change in Cash9.97M(15.71M)(1.59M)48.44M46.93M
Free Cash Flow(13.05M)(15.91M)(18.01M)(19.58M)(23.61M)

Benitec Biopharma Inc.

NASDAQ:BNTC

Intrinsic Alpha fair value

Locked

Current Price

$8.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.